EN | RU
EN | RU

Help Support

Back

JAK inhibitor and type I interferon therapy yield positive outcomes in COVID-19 patients

JAK inhibitor and type I interferon therapy yield positive outcomes in COVID-19 patients JAK inhibitor and type I interferon therapy yield positive outcomes in COVID-19 patients
JAK inhibitor and type I interferon therapy yield positive outcomes in COVID-19 patients JAK inhibitor and type I interferon therapy yield positive outcomes in COVID-19 patients

A meta-analysis and systematic review were carried to investigate type I interferons and JAK-inhibitors for their efficacy and ability to yield positive outcomes in individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 

See All

Key take away

A study demonstrated that janus kinase (JAK)-inhibitor therapy is considerably linked with positive clinical outcomes in terms of mortality, intensive care unit admission, and discharge. Regarding mortality and discharge, the type I interferon therapy is linked with favorable clinical outcomes.

Background

A meta-analysis and systematic review were carried to investigate type I interferons and JAK-inhibitors for their efficacy and ability to yield positive outcomes in individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 

Method

To incorporate any study type that assessed therapy outcomes of subjects receiving JAK-inhibitor or type I interferon against controls, MEDLINE and MedRxiv were explored  The inclusion necessitated data with clearly depicted risk estimates or those that allowed their back-calculation. Utilizing RevMan, the outcomes were assessed.

Result

Out of 733 searched studies, eleven non-randomized and four randomized trials were incorporated. Notably, five studies were unpublished. Participants receiving Janus kinase-inhibitor had considerably declined odds of mortality (OR 0.12) and ICU admission (Odds ratio [OR] 0.05) and had substantially elevated odds of hospital discharge (OR 22.76) in comparison with the participants receiving standard therapy. Patients treated with type I interferon had remarkably declined odds of mortality (OR 0.19), and elevated odds of discharge bordering significance (OR 1.89).

Conclusion

JAK-inhibitors and type I interferons appear to be promising agents to combat coronavirus infection. Further well-conducted and robust randomized controlled trials  are required to elucidate the relationship between clinical outcomes and JAK-inhibitors and type I interferons in coronavirus-infected patients.

Source:

BMC Infectious Diseases

Article:

JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis

Authors:

Lucas Walz et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: